ASCO: Pfizer's Ibrance fails to extend lives in newly diagnosed breast cancer. Will doctors switch gears to Novartis, Lilly?

The verdict is in: Pfizer’s Ibrance didn’t improve the life span of patients with newly diagnosed HR-positive, HER2-negative breast cancer in a first-of-its-kind clinical trial.